Opko Health Inc. (OPK): Today's Featured Health Services Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Opko Health ( OPK) pushed the Health Services industry lower today making it today's featured Health Services laggard. The industry as a whole closed the day up 0.7%. By the end of trading, Opko Health fell $0.15 (-1.7%) to $8.85 on average volume. Throughout the day, 3,520,242 shares of Opko Health exchanged hands as compared to its average daily volume of 4,683,200 shares. The stock ranged in price between $8.73-$9.15 after having opened the day at $9.03 as compared to the previous trading day's close of $9.00. Other companies within the Health Services industry that declined today were: Cardica ( CRDC), down 8.3%, Navidea Biopharmaceuticals ( NAVB), down 4.5%, Rosetta Genomics ( ROSG), down 4.4% and Fonar Corporation ( FONR), down 4.3%.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Opko Health has a market cap of $3.6 billion and is part of the health care sector. Shares are up 6.6% year to date as of the close of trading on Tuesday. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow.

On the positive front, Globus Medical ( GMED), up 12.1%, Foundation Medicine ( FMI), up 11.8%, InspireMD ( NSPR), up 9.9% and Hooper Holmes ( HH), up 9.4% , were all gainers within the health services industry with Boston Scientific ( BSX) being today's featured health services industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Blame the Millennials: Cramer's 'Mad Money' Recap (Wednesday 8/9/17)

Biotech Movers: Paratek, Opko, Endo

Insiders Are Loading Up on GE, Twilio & More

Ford Motor, Constellation Brands, Cypress Semiconductor: 'Mad Money' Lightning Round